product continu drive bulk growth
eylea dupix libtayo drive major top-lin growth
eylea dupix libtayo major top-lin driver
expect trend continu eylea think eylea like
get tailwind sale pre-filled syring come fulli on-line
howev remain focus competit outyear sinc sever
vegf product go similar indic alreadi phase bla
phase furthermor beovu initi launch continu keep eye
sale trajectori novarti manag mention earn call
retina specialist stock product fridg although suspect incent
might exist promot beovu use earli stage launch dupix
libtayo expect revenu continu grow addit indic ad
sale continu ramp dtc campaign increas sale forc size also
help drive addit sale two product
interim libtayo surviv data nsclc data key data catalyst
libtayo full phase interim phase data nsclc major catalyst
await detail time also await addit data
own product compet larg rituxan market dlbcl
indic libtayo believ must gener data least equival
keytruda high express patient may posit libtayo favor
vs bmi opdivo care monitor safeti
care dose escal avoid advers event
sanofi collabor restructur welcom move toward own
obtain definit detail sanofi collabor restructur toward
end first quarter accord manag favor
obtain wholli own asset control product
potenti increas oper margin thu far compani express
interest us praluent right increas dupix exposur although
still sure abl amend agreement fit interest
long-term think addit dupix exposur could signific driver top-
line growth get
maintain hold rais pt
maintain hold rate base risk addit competitor price
concern relat eylea addit note may sever headwind
compani includ dupix patent ipr/ litig continu price concern
eylea medicar part price initi addit eylea competit
join fray rais pt howev sinc expect stronger growth
dupix libtayo eylea diabet indic reiter
think eylea revenu may diminish outyear competit product obtain
greater market share time similar indic also encourag
potenti sanofi agreement restructur could give wholli own
product increas oper margin
price close busi februari
biotech
discov invent manufactur
commerci medicin treat seriou
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object
view compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
hold unchang target price februari
may dataphas data osteoarthr pain knee hipinterim phase datainterim analysi os nsclc monotherapyphas datapivot phase data patientsphas data r/r data potenti phase data potenti phase data r/r b-cell malignanciesfda decis sbla expand ad indic pediatr patient year phase dataphas studi asthma pediatr patient year old phase dataphas portion data eosinophil esophag patient figur cg vs consensu
hold unchang target price februari
hold unchang target price februari
hold unchang target price februari
fy producteyleau ex-u arcalystu ex-u revenues- libtay ex-u revenues- net product sale book praluentu ex-u ww zaltrapex-u us ww kevzarau ex-u dupixentu ex-u regeneron pharmaceut
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may
obtain contact canaccord genuiti sale person author analyst whose contact inform appear front page report
hold unchang target price februari
fy bayer collabor technolog net product contract research other- total good option expensegross oper expensesresearch reimburs sanofi bayer teva option non-reimburs sell gener option expens sg ex-opt collabor total oper profit loss oper profit loss incom expens incom expens loss earli extinguish debtpre-tax incom pre-tax incom tax rate tax expens benefit tax rate tax expens benefit net incom loss adjust net net incom loss ep fulli ep fulli share dilut share regeneron pharmaceut
hold unchang target price februari
regeneron pharmaceut balanc market receiv trade receiv sanofi plant tax asset asset liabil account payabl accru expens leas total stockhold equiti total liabil stockhold equiti regeneron pharmaceut
